S. Hominal

1.2k total citations
27 papers, 422 citations indexed

About

S. Hominal is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, S. Hominal has authored 27 papers receiving a total of 422 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 3 papers in Surgery. Recurrent topics in S. Hominal's work include Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Lung Cancer Research Studies (6 papers). S. Hominal is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Lung Cancer Research Studies (6 papers). S. Hominal collaborates with scholars based in France, Luxembourg and United Kingdom. S. Hominal's co-authors include I. Martel, David Pérol, D. Arpin, L. Claude, C. Ginestet, Michel Vincent, C. Carrié, Jean-François Cordier, L. Falchero and C. Chouaïd and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

S. Hominal

23 papers receiving 414 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Hominal France	9	340	134	134	109	102	27	422
Ronald Shapiro United States	9	328 1.0×	69 0.5×	163 1.2×	233 2.1×	44 0.4×	17	455
Melissa A.L. Vyfhuis United States	10	201 0.6×	182 1.4×	60 0.4×	89 0.8×	49 0.5×	30	390
Joanne Meng Canada	6	380 1.1×	176 1.3×	166 1.2×	176 1.6×	33 0.3×	7	508
J. McAleese United Kingdom	15	282 0.8×	95 0.7×	202 1.5×	132 1.2×	29 0.3×	48	478
Qiuan Yang China	11	311 0.9×	82 0.6×	109 0.8×	178 1.6×	41 0.4×	23	445
Matteo Muto Italy	11	208 0.6×	61 0.5×	90 0.7×	78 0.7×	45 0.4×	30	330
Yuichiro Tsurugai Japan	11	272 0.8×	83 0.6×	159 1.2×	181 1.7×	56 0.5×	29	557
C. Lochrin Canada	9	214 0.6×	99 0.7×	81 0.6×	88 0.8×	28 0.3×	15	336
Marisol Arroyo‐Hernández Mexico	7	218 0.6×	123 0.9×	165 1.2×	45 0.4×	27 0.3×	12	363
Daniel J. Tandberg United States	9	232 0.7×	84 0.6×	50 0.4×	46 0.4×	37 0.4×	18	327

Countries citing papers authored by S. Hominal

Since Specialization

Citations

This map shows the geographic impact of S. Hominal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Hominal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Hominal more than expected).

Fields of papers citing papers by S. Hominal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Hominal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Hominal. The network helps show where S. Hominal may publish in the future.

Co-authorship network of co-authors of S. Hominal

This figure shows the co-authorship network connecting the top 25 collaborators of S. Hominal. A scholar is included among the top collaborators of S. Hominal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Hominal. S. Hominal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leblanc, Serge, Michaël Génin, Florent Occelli, et al.. (2024). Association épidémiologique entre pollution et altérations oncogéniques dans le cancer du poumon. Revue des Maladies Respiratoires Actualités. 16(1). 19–20.

Léna, H., Laurent Greillier, Claire Cropet, et al.. (2024). Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study. The Lancet Respiratory Medicine. 13(2). 141–152. 5 indexed citations

Bylicki, Olivier, Florian Guisier, Arnaud Scherpereel, et al.. (2024). Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04–2021) trial. Lung Cancer. 194. 107866–107866. 8 indexed citations

Falchero, L., Olivier Molinier, Faraj Al Freijat, et al.. (2024). Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting. European Journal of Cancer. 210. 114277–114277. 2 indexed citations

Vergnenègre, A., I. Monnet, Charles Ricordel, et al.. (2023). Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo). Lung Cancer. 178. 191–197. 5 indexed citations

Bylicki, Olivier, Florian Guisier, Catherine Daniel, et al.. (2023). Real-life efficacy of nivolumab plus ipilimumab combination in untreated, unresectable malignant pleural mesotheliomas: Result of French early access program—MESOIMMUNE – GFPC 04-2021.. Journal of Clinical Oncology. 41(16_suppl). 8536–8536.

Swalduz, Aurélie, G Le Moël, D. Debieuvre, et al.. (2023). LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer.. Journal of Clinical Oncology. 41(16_suppl). 9019–9019. 11 indexed citations

Blons, Hélène, Jean‐Philippe Merlio, D. Debieuvre, et al.. (2020). PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project. Lung Cancer. 151. 69–75. 7 indexed citations

Trédaniel, Jean, L. Moreau, J. Le Treut, et al.. (2020). Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study. Respiratory Medicine and Research. 80. 100795–100795. 9 indexed citations

10.

Blons, Hélène, Jean‐Baptiste Oudart, Jean‐Philippe Merlio, et al.. (2018). Molecular heterogeneity assessment by NGS in non-small cell lung cancer (NSCLC) harboring EGFR mutations: Results of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study. Annals of Oncology. 29. viii39–viii40. 1 indexed citations

11.

Grivaux, M, Bernard Duvert, S. Hominal, et al.. (2016). Amélioration de la survie à 1 an dans le cancer du poumon en France. Résultats des études prospectives en vie réelle, KBP-2000-CPHG et KBP-2010-CPHG. Revue de Pneumologie Clinique. 72(3). 163–170. 5 indexed citations

12.

Chouaïd, C., C. Dujon, Pascal Dô, et al.. (2014). Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01). Lung Cancer. 86(2). 170–173. 132 indexed citations

13.

Decroisette, C., et al.. (2013). Épidémiologie, prise en charge et coût des métastases osseuses des cancers bronchopulmonaires (hors métastases rachidiennes). Revue des Maladies Respiratoires. 30(4). 309–315. 5 indexed citations

14.

Vergnenègre, A., S. Hominal, Achille Tchalla, et al.. (2013). Assessment of palliative care for advanced non-small-cell lung cancer in France: A prospective observational multicenter study (GFPC 0804 study). Lung Cancer. 82(2). 353–357. 9 indexed citations

15.

Hominal, S., et al.. (2004). Dosage du BNP sur ADVIA Centaur (Bayer HealthCare) : corrélation avec la technique Triage (Biosite) et application au diagnostic étiologique d’une dyspnée. Immuno-analyse & Biologie Spécialisée. 19(5). 286–293. 1 indexed citations

16.

Claude, L., David Pérol, C. Ginestet, et al.. (2004). A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiotherapy and Oncology. 71(2). 175–181. 168 indexed citations

17.

Pujol, Jean-Louis, B. Milleron, Élisabeth Quoix, et al.. (2003). P-532 Multicenter phase II trial of weekly taxol and paraplatine as first line treatment in elderly patients with non small cell lung cancer (NSCLC): preliminary results. Lung Cancer. 41. S226–S226. 1 indexed citations

18.

Tahon, F., Yves Berthezène, S. Hominal, et al.. (2002). Exogenous lipoid pneumonia with unusual CT pattern and FDG positron emission tomography scan findings. European Radiology. 12(S3). S171–S173. 20 indexed citations

19.

Hominal, S., Isabelle Martel‐Lafay, M. Pérol, et al.. (2000). Conformal radiotherapy as an alternative to surgery for respiratory inoperable stage I non-small cell lung cancer (NSCLC). Lung Cancer. 29(1). 170–170. 1 indexed citations

20.

Hominal, S., et al.. (1999). [Carcinomatous lymphangitis].. PubMed. 28(18). 979–84. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact